`Transaction ID 57319242
`Case No. 11076-VCL
`
` ei 3
`
`IN THE COURT OF CHANCERYOF THE STATE OF DELAWARE
`
`BRISTOL-MYERS SQUIBBCO.,
`
`Plaintiff,
`
`V.
`
`DAVID BERMAN,
`
`Defendant.
`
`Civil Action No. 11076-VCL
`
`AFFIDAVIT OF BAHIJA JALLAL
`
`1.
`
`This Affidavit is based upon my personal knowledge. I am giving this
`
`Affidavit in opposition to BMS’s Motion for a Temporary Restraining Order
`
`against Defendant David Berman.
`
`2.
`
`I am currently employed as Executive Vice President of AstraZeneca
`
`Pharmaceuticals LP (“AZ”) and the head of MedImmune, LLC (“MedImmune”),
`
`AZ’s global biologics research and development arm.
`
`3.
`
`MedImmune is arranged into five disease-focused units for
`
`the
`
`discovery and developmentof new biologics. Oncology is one ofthese five units.
`
`4.
`
`MedImmune’s oncology research pipeline targets solid tumors (such
`
`as breast or lung cancers) and hematologic cancers (such as lymphoma and
`
`leukemia).
`
`5.
`
`A main focus at MedImmuneis incorporating innovative technologies
`
`designed to eliminate cancer cells in more effective and targeted ways, such as
`
`118207706_1
`
`1
`
`EFiled: Jun 01 2015 07:22PM EDT
`Transaction ID 57319242
`Case No. 11076-VCL
`
`
`
`
`
`
`
`
`
`effector-enhanced, polyspecific, and toxin-carrying antibodies. This includes a
`
`focus on several
`
`strategic biologic areas critical
`
`to the development and
`
`progression of cancer:
`
`immune-mediated cancer therapy
`tumor-associated antigens
`cancer stem cells
`growth factor signaling and survival
`
`6.|MedImmune is aware of Dr. Berman’s post-employment obligations
`
`to BMS.
`
`7.
`
`Indeed, MedImmune has expressly cautioned Dr. Berman against
`
`using or disclosing any of BMS’s confidential information to which he may be
`
`privy.
`
`8.
`
`MedImmune does not believe that Dr. Berman’s obligations to BMS
`
`preclude his employment with MedImmune.
`
`9,
`
`MedImmune has a substantial number of drugs under development
`
`which do not compete with any of the drugs that Dr. Berman wasinvolved in over
`
`the last
`
`twelve months of his employment with BMS (hereafter,
`
`the “BMS
`
`Restricted Drugs”).
`
`10. As such, Dr. Berman’s role at MedImmune would not require him to
`
`use or disclose any of BMS’s confidential information.
`
`118207706_1
`
`
`
`11. However,
`
`to the extent
`
`that
`
`there are drugs in development at
`
`MedImmune or AZ that compete with any of the BMS Restricted Drugs,
`
`MedImmune will implement safeguards to ensure that Dr. Berman will not have
`
`any involvement with such drugs over the next twelve months.
`
`12.
`
`If Dr. Berman is asked to become involved in any way with such
`
`drugs over the next twelve months, he is to refuse to do so and alert me ofthe
`
`request so that I arrange for another senior oncology executive to handle whatever
`
`task may have been asked of Dr. Berman.
`
`13.
`
`In short, MedImmune does not want Dr. Berman to engage in any
`
`activity that could violate his post-employmentobligations to BMS.
`
`14.
`
`Indeed, MedImmuneis altering the original requirements of the
`
`position for which Dr. Berman washired and is creating a job description that
`
`specifically takes into accounthis obligations to BMS.
`
`15.
`
`I swear under penalty of perjury that the foregoingis trw¢
`
`and correct.
`
`
`
`Sworn to and subscribed before me
`this_/$*__
`day of _Junly
`NOTARY PUBLIC
`
`C
`
`S
`
`My Commission Expires: qv/[2016
`
`118207706_1
`
`2015,
`
`
`
`OFFICIAL SEAL
`NILMAR O MENDOZA
`NOTARY PUBLIC - STATE OF ILLINOIS
`MYCOMMISSIONEXPIRES:0702/16
`
`
`
`
`
`